Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ibrance is a prescription kinase inhibitor containing palbociclib. Current U.S. labeling includes several combination regimens for hormone receptor-positive advanced or metastatic breast cancer, including HER2-negative disease and a 2026 maintenance indication for selected HER2-positive disease.
read more about ibrance ...Palbociclib inhibits cyclin-dependent kinases 4 and 6. Blocking CDK4 and CDK6 reduces retinoblastoma protein phosphorylation and interferes with progression from the G1 phase to the S phase of the cell cycle. This reduces proliferation of susceptible breast cancer cells.
Ibrance is used in adults with HR-positive HER2-negative advanced or metastatic breast cancer in combination with specified endocrine therapies. It is also used with inavolisib and fulvestrant for selected PIK3CA-mutated disease. Current labeling also includes maintenance treatment of HR-positive HER2-positive locally advanced or metastatic breast cancer after induction therapy with trastuzumab, with or without pertuzumab, plus endocrine therapy.
The recommended starting dose is 125 mg once daily for 21 consecutive days followed by seven days without Ibrance, creating a 28-day cycle. Capsules are taken with food, while tablets can be taken with or without food. Dose reductions to 100 mg and then 75 mg are used for selected adverse reactions.
Serious concerns include neutropenia, interstitial lung disease or pneumonitis, infections related to low white blood cell counts, and fetal harm. Complete blood counts are checked before treatment, at the start of each cycle, on day 15 of the first two cycles, and at other clinically indicated times. Strong CYP3A inhibitors and inducers can alter palbociclib exposure.
Ibrance is a CDK4 and CDK6 inhibitor containing palbociclib.
The standard starting regimen is 125 mg once daily for 21 days followed by seven days without Ibrance.
Yes. Current labeling includes a maintenance regimen for selected HR-positive HER2-positive locally advanced or metastatic breast cancer after induction treatment.
Neutropenia is a common and clinically significant adverse reaction, so complete blood counts are monitored during therapy.
DailyMed - IBRANCE (palbociclib) capsule. https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07. Date Accessed October 1, 2026.
IBRANCE (palbociclib) Prescribing Information. Pfizer. https://labeling.pfizer.com/ShowLabeling.aspx?format=PDF&id=12921. Date Accessed October 1, 2026.
Palbociclib. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a615013.html. Date Accessed October 1, 2026.
Palbociclib. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/palbociclib. Date Accessed October 1, 2026.
Palbociclib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Palbociclib. Date Accessed October 1, 2026.